bioAffinity Technologies: CyPath Lung sales up more than 100% through Q3 2026

What happened On Oct 6, 2026, bioAffinity Technologies, Inc. announced that sales of its CyPath® Lung test for lung cancer increased more than 100% through the 3rd quarter of 2026 compared to 2025, reflecting continued growth in clinical adoption of the Company’s noninvasive test for assessing the likelihood of lung cancer in high-risk individuals. The press release is attached as Exhibit 99.1 and is incorporated by reference in the filing.

Key details

• Announcement date: Oct 6, 2026.
• Reported change: sales of the CyPath® Lung test increased more than 100% through the 3rd quarter of 2026 versus 2025.
• Test described: CyPath® Lung, a noninvasive test for assessing the likelihood of lung cancer in high-risk individuals.
• Filing item: Item 8.01 (Other Events).

Why it may matter The 8-K reports an Item 8.01 Other Events disclosure, which covers the Company’s press release announcing the sales increase for the CyPath® Lung test. This filing does not show why the insider traded or why the company acted.